Hemab Therapeutics Holdings, Inc. (Ticker: COAG) is a pioneering biopharmaceutical company dedicated to developing innovative therapies for rare bleeding disorders and other hematologic conditions. With a proprietary technology platform and a strong pipeline of drug candidates, Hemab aims to address significant unmet medical needs in hematology. The company's commitment to rigorous research and development, complemented by strategic partnerships, positions it favorably within the fast-evolving biotechnology landscape. Hemab's mission to enhance patient outcomes underscores its potential as an attractive investment opportunity for institutional investors seeking to capitalize on advancements in this critical healthcare sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-86.89M |
| Operating Margin | 0.00% |
| Return on Equity | -47.00% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.73 |
| Price-to-Book | 3.78 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $46.71M |
| Float | $20.31M |
| % Insiders | 10.78% |
| % Institutions | 92.32% |
Volatility is currently contracting
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare professional in the U.S. last year.
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets.
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway
Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab's common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, were approximately $346.7 million.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COAG and any ticker you trade — then tracks every position and per-strategy win rate.
